Researchers are investigating whether restoring vitamin C levels can influence biology of early blood disorders before leukemia develops. A clinical trial suggests that correcting vitamin C deficiency may benefit people with certain blood disorders that can precede leukemia.
Results from the randomized, double-blind, placebo-controlled phase 2 EVITA trial found that participants who took 1,000 mg of oral vitamin C daily for one year experienced fewer adverse events during study and follow-up period than those given placebo. The study, led by the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, included 109 people with clonal cytopenia of undetermined significance, or CCUS, or myelodysplastic syndrome, or MDS, both of which can progress to acute myeloid leukemia, or AML.
A Possible Survival Signal at 3 Years
Findings, published in the American Cancer Society journal CANCER, also showed that vitamin C changed levels of cytokines, molecules involved in inflammation and immune signaling. Changes were associated with more favorable outcomes and may indicate that vitamin C affects pathways involved in abnormal blood cell growth.
Researchers did not find a significant difference between vitamin C and placebo groups in expansion of abnormal blood cell clones, a measure used to track progression toward leukemia. However, an exploratory analysis found that after about three years of follow-up, participants who received vitamin C were significantly more likely to be alive than those given placebo. Because this result came from exploratory analysis in relatively small phase 2 trial, it needs confirmation in larger phase 3 study.
“We are tremendously excited and cautiously optimistic that our results could one day translate into a simple way to improve care and outcomes for people with pre-leukemia disorders,” said Peter A. Jones, Ph.D., D.Sc. (hon), distinguished professor at Van Andel Institute, co-corresponding author and co-leader of VAI–SU2C Epigenetics Dream Team.
“Our approach reflects a growing emphasis on cancer interception — intervening before cancer becomes established. We are working to build on trial findings by exploring how exactly vitamin C interacts with pre-cancerous cells, including idea that it may help restore normal epigenetic function in blood cells at risk of becoming leukemia.”
Why Vitamin C May Matter: TET2 and Epigenetic Regulation
More than half of participants were vitamin C deficient when trial began. Blood testing showed vitamin C levels normalized in those assigned to supplementation.
Vitamin C has roles beyond immune function and wound healing. It also supports enzymes involved in epigenetic regulation, which controls gene activity without changing underlying DNA sequence.
One important enzyme is TET2. Mutations in TET2 are common in leukemia and related blood disorders and can give abnormal blood-forming cells a growth advantage. Laboratory and animal studies have suggested vitamin C can support remaining TET activity and may limit some cancer-related cellular changes. Earlier studies often tested intravenous vitamin C, which produces much higher blood concentrations than oral supplements. EVITA instead examined whether daily oral dose could correct vitamin C deficiency and affect early disease biology.
An Option for Patients With Few Preventive Treatments
There is currently no approved therapy specifically designed to prevent CCUS from progressing to leukemia. MDS can sometimes be treated with stem cell transplantation, but age and other health conditions may make procedure unsuitable for many patients.
“The standard approach for patients with pre-cancer blood disorders is to monitor their blood cell counts over time. This is, understandably, very frustrating — no one wants to hear that they have a condition that increases leukemia risk, but there’s nothing that can be done other than watch and wait,” said Casey O’Connell, M.D., FACP, the Lawrence and Jane Kelly Chair in Hematology at University of Southern California and lead clinician for USC’s trial site.
“The EVITA trial took on this challenge by exploring vitamin C’s potential to address underlying factors that drive leukemia development.”
International study was led by Kirsten Grønbæk, M.D., Ph.D., hematologist, member of VAI–SU2C Epigenetics Dream Team, and professor at University of Copenhagen. “These exciting preliminary findings lay groundwork for larger clinical trial to explore vitamin C as possible way to improve patient outcomes,” said Grønbæk. “It is too early to make definitive recommendations based on our results, but we are hopeful that more expansive study will provide further insights.”
Researchers are continuing to analyze trial data, including biological mechanisms that may help explain survival difference between groups.
Analysis: What EVITA Does and Does Not Show
1. Deficiency correction, not megadose: Over 50% were deficient at baseline. Benefit came from normalizing levels with 1,000 mg oral daily, not IV high-dose vitamin C.
2. Survival signal exploratory: Fewer adverse events and higher survival at ∼3 years were seen, but clone expansion primary endpoint was not significantly different, and survival finding was exploratory in 109-patient phase 2 trial.
3. Mechanistic clue: Cytokine changes linked to favorable outcomes support hypothesis that vitamin C affects inflammation and epigenetic pathways via TET2 support, needing further validation.
4. Unmet need context: CCUS has no approved preventive therapy and is often managed with watch and wait, making even low-cost, low-toxicity interception strategies highly relevant if confirmed in phase 3.
Q&A
Q: Can vitamin C prevent leukemia?
A: Not proven. EVITA phase 2 trial in 109 CCUS and MDS patients found 1,000 mg oral vitamin C daily for 1 year corrected deficiency, reduced adverse events, and showed exploratory survival advantage at 3 years, but needs phase 3 confirmation.
Q: What is CCUS and MDS?
A: Clonal cytopenia of undetermined significance and myelodysplastic syndrome are blood disorders where abnormal clones expand and can progress to acute myeloid leukemia. CCUS currently has no approved preventive therapy.
Q: Why vitamin C and TET2?
A: Vitamin C supports TET enzymes involved in epigenetic regulation. TET2 mutations are common in these disorders, and lab studies suggest vitamin C may support remaining TET activity.
FAQ
1. What dose was used in EVITA?
1,000 mg oral vitamin C daily for one year versus placebo, in randomized double-blind phase 2 trial.
2. Who led the trial?
Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, led by Kirsten Grønbæk University of Copenhagen, Peter A. Jones Van Andel Institute, and Casey O’Connell USC.
3. Did vitamin C stop clone expansion?
No significant difference between groups in abnormal clone expansion, the measure tracking progression toward leukemia.
4. Was vitamin C safe?
Participants on vitamin C had fewer adverse events during study and follow-up than placebo, but safety in broader populations needs larger trials.
5. Should CCUS or MDS patients take vitamin C now?
Researchers say too early for definitive recommendations. Patients should discuss deficiency testing and supplementation only with their hematologist.
Disclaimer: This article does not provide medical advice, diagnosis, or treatment recommendations.
